Keywords: FDA, UCB, Sanofi-Aventis, Xyzal, approval

US FDA clears UCB/Sanofi-Aventis’ Xyzal for children

Article | 25 August 2009

Print This

Belgium drugmaker UCB and French partner Sanofi-Aventis’s US subsidiary say that the US Food and Drug Administration has approved ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in